Open AccessAllogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Author(s) -
Qaiser Bashir,
Denái R. Milton,
Uday Popat,
Partow Kebriaei,
Chitra Hosing,
Issa F. Khouri,
Katayoun Rezvani,
Yago Nieto,
Betül Oran,
Samer A. Srour,
Neeraj Saini,
Amanda Olson,
Gheath Alatrash,
Gabriela Rondón,
Marina Konopleva,
Richard E. Champlin,
Elizabeth J. Shpall,
Muzaffar H. Qazilbash,
Naveen Pemmaraju
Publication year - 2021
Publication title -
bone marrow transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 127
eISSN - 1476-5365
pISSN - 0268-3369
DOI - 10.1038/s41409-021-01478-5
Subject(s) - medicine , transplantation , cumulative incidence , hematopoietic cell , gastroenterology , bone marrow , hematopoietic stem cell transplantation , hematologic malignancy , malignancy , incidence (geometry) , hematology , haematopoiesis , graft versus host disease , surgery , stem cell , physics , biology , optics , genetics
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematological malignancy; however, some patients achieve durable remission with allogeneic hematopoietic cell transplantation (allo-HCT). We report on all 17 patients with BPDCN who underwent allo-HCT at our center between 2000 and 2020. The median age was 39 (18-67) years. All (n = 16, 94%), except one patient, had systemic disease involving bone marrow and/or other organs. Ten patients (59%) were in first complete remission (CR1) at allo-HCT. The donor source was matched related or unrelated in ten (59%) and alternate donor in seven (41%) patients. Five (31%) patients developed acute graft-versus-host disease (GVHD), all grade I-II. The cumulative incidence (CI) of chronic GVHD at five-year was 34%. The CI of non-relapse mortality at one-year was 29%. Progression-free survival (PFS) rates at two-year and five-year were 49% (95% CI = 22-71%) and 39% (95% CI = 14-64%), respectively. The two-year and five-year overall survival (OS) rates were 65% (95% CI = 38-82%) and 40% (95% CI = 12-68%), respectively. The five-year rate for both PFS and OS was 80% in CR1 patients versus 0% in patients not in CR1. In conclusion, allo-HCT provides long-lasting remissions in BPDCN patients, particularly when performed in CR1.